Ribbon Acquisition Corp.

What they do

Ribbon Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has no operating business of its own and has not generated revenue from operations; its principal activities are identifying, negotiating and completing a business combination and maintaining the trust account funded by its IPO proceeds. On June 30, 2025, it entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd. and DRC Merger Inc., which remains pending as of the latest 10-Q.

Revenue drivers

• Trust account interest income — The company's reported income comes from interest earned on the funds held in its investment management trust account, not from operating revenue; annual net income was $690,218 for 2025.
• IPO and private placement proceeds — The company funds itself with cash from its initial public offering, private placement units and related instruments; these proceeds are held in trust and are not available for general operating use except as permitted by the trust agreement.
• Sponsor notes and extension deposits — The company has relied on a promissory note to Ribbon Investment Company Ltd. ($600,000 principal, issued March 7, 2026, non-interest bearing and payable after an initial business combination) and monthly $125,000 trust deposits for extensions.
• Post-combination equity or debt issuance — Management states it intends to effectuate an initial business combination using cash from the IPO and private placement, proceeds of securities sales, shares, debt, or a combination of cash, stock and debt.

Recent performance

For fiscal year 2025, Ribbon reported net income of $690,218 and operating cash flow of negative $699,419. As of June 30, 2026, total assets were $38.5 million, total liabilities were $3.8 million, shareholder equity was negative $374,721, and cash and equivalents were only $669. The company remains a blank check company with no operating revenue, and its assets are primarily the trust account. It has continued to fund monthly trust extensions, depositing $125,000 per month, including on July 14, 2026.

Strategy

Management's stated intent is to complete an initial business combination, and it has signed a Business Combination Agreement dated June 30, 2025 with DRC Medicine Inc., DRC Medicine Ltd. and DRC Merger Inc. It expects to incur significant costs pursuing its acquisition plans and cannot assure that these plans will be successful. On January 9, 2026, shareholders approved extending the deadline to consummate a business combination from January 16, 2026 to January 16, 2027, and approved $125,000 monthly extension payments into the trust account. The company has also sought approval to revise the monthly extension contribution to a maximum of $50,000 per month, with the related extraordinary general meeting adjourned multiple times, including to April 13, 2026 and then to September 14, 2026.

Risks

• Failure to complete a business combination — The company may be unable to consummate the pending DRC Medicine combination or another initial business combination, which would force it to liquidate and return trust funds to public shareholders.
• Going concern and liquidity — At June 30, 2026, cash and equivalents were $669 and shareholder equity was negative $374,721, leaving the company dependent on sponsor loans and extension deposits to fund operations.
• Delisting or listing-rule failure — The company disclosed a delisting notice or listing-rule failure event on June 5, 2026, and continued Nasdaq listing is not assured.
• Dilutive redemptions and extension costs — In connection with the January 9, 2026 special meeting, holders of 1,436,867 public shares exercised redemption rights, and the company has been depositing $125,000 monthly into the trust account for extensions, consuming cash and reducing the trust balance available for a deal.

Outlook

Management states there have been no material changes to the terms of the June 30, 2025 Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd. and DRC Merger Inc. as of the latest 10-Q. The company must consummate an initial business combination by January 16, 2027, as extended at the January 9, 2026 shareholder meeting, subject to monthly $125,000 trust deposits. It continues to seek shareholder approval to lower the monthly extension contribution to a maximum of $50,000, with the meeting adjourned to September 14, 2026. Management notes that it cannot assure its plans to complete an initial business combination will be successful.